Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025Virology JournalOpen Access

Methylprednisolone pulse therapy compared with intravenous dexamethasone for severe COVID-19 patients: a randomized clinical trial

View Full Paper
Ask AI
Bookmark
Share

Authors

KHKaveh HaratianAAA AlaeiGMGolbarg Mehrpoor

Discussion

Loading...

Member takes

Overview

Randomized clinical trial compares mortality and ICU stay for dexamethasone and methylprednisolone in COVID-19 patients, indicating similar efficacy.

Key Points

  • Mortality rates showed no significant difference, with 12.6% for dexamethasone versus 15.3% for methylprednisolone.
  • ICU stay was significantly shorter for dexamethasone at 9.5 days compared to 11.3 days for methylprednisolone.
  • The need for mechanical ventilation was observed in 16.6% of patients receiving dexamethasone, while it was 21.3% for methylprednisolone.
  • Both treatments had a similar impact on blood oxygen saturation levels in patients hospitalized with COVID-19.

Cite This Study

Haratian et al. (2025) studied this question.

synapsesocial.com/papers/68c1bb5b54b1d3bfb60ecea0https://doi.org/10.1186/s12985-025-02906-4
View Full Paper
Ask AI
Bookmark
Share